The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium, of which the Vall d´Hebron Institute of Oncology (VHIO) is Member, proudly announces that Oracle Health Sciences has become a member of the consortium. Oracle will provide access to its data management, clinical trials, genomics and analytics expertise to help WIN advance its mission of increasing the efficacy of cancer care globally through personalized therapy and early diagnostics.
The development of personalized therapies requires new collaborations between industry, healthcare and academia. This includes the ability to access and build upon the collective knowledge and data of the entire cancer community, including clinical, genomic and patient data leveraging modern information technologies.
Oracle Health Sciences has developed a portfolio of integrated, cloud-based software applications that help advance personalized medicine by enabling new collaboration models between research institutions and healthcare organizations. Specific to the work of the consortium, the Oracle Health Sciences Network accelerates translational research, healthcare analytics, and health information exchange by allowing these organizations to more efficiently share and analyze de-identified data across organizational boundaries.
“To advance personalized cancer care, collaboration among the health sciences community is absolutely essential, but achieving it, from a technology perspective, has presented challenges. Oracle is helping organizations to break down these barriers and lay a foundation for expanded collaboration and new insight. We welcome Oracle’s knowledge and innovation as it joins our ranks,” said Dr. John Mendelsohn, Chairman of WIN Consortium and past President, University of Texas MD Anderson Cancer Center.
“Our overarching goals are to achieve groundbreaking personalized cancer medicine discoveries and to significantly improve the outcomes and quality of life for cancer patients,” said Professor Alexander Eggermont, General Director, Institut Gustave Roussy and Vice-Chairman of WIN Consortium. “With the dropping cost of whole genome sequencing, technology is essential to helping us analyze this rich data and achieve our goals. We welcome Oracle, one of the world’s leading innovators in this field, to our organization, and look forward to its many contributions.”
“Oracle is extremely proud to join the WIN Consortium and contribute to this important initiative,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “Our health sciences solutions, which support greater collaboration across the healthcare and life sciences community and help to fuel insight, complement WIN’s unique approach. We look forward to applying our solutions and expertise to advance its mission.”
“The productive and positive power of partnerships to drive progress in medical science cannot be underestimated and must be encouraged. It is in this spirit that I enthusiastically joined the Prix Galien USA Committee,” said Professor Paul A. Marks, M.D., Laboratory Head of Cell Biology, Memorial Sloan Kettering Cancer Center, New-York, President, Emeritus, MSKCC. “By joining WIN and sharing its genetic and analytics expertise with the community, Oracle can make a powerful contribution to the WIN consortium’s mission of advancing personalized cancer care.”
WIN Consortium is a network of 22 academic institutions and industries across the globe, initiated by Cancer Institute Gustave Roussy (IGR), France, and University of Texas MD Anderson Cancer Center (MDACC), USA, focusing on biomarker-driven therapeutic clinical trials conducted worldwide.
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
For further information, please visit
Catherine Bresson: Director Operational Team
For information concerning VHIO´s involvement in the WIN Consortium please contact Amanda Wren, Communication Manager at VHIO: firstname.lastname@example.org.